[15] This signal has not been confirmed in humans, but it is reflected in the prescribing information for approved GLP-1-based medicines such as semaglutide (see the UK Summary of Product Characteristics for Wegovy, available via the electronic Medicines Compendium)
le Roux CW, Davies M, Frias JP, Jensen C, Nrkjr Laursen P, Lingvay I, Machineni S, Varbo A, Wilding JPH, Perreault L
Zadoorian A, Du X, Yang H
Long-term risks of Trulicity include the potential worsening of or new onset kidney damage and severe digestive problems such as gastroparesis or ileus
Amino acids from protein serve as building blocks for neurotransmitters
Blood tests and ultrasound help confirm the diagnosis